Analytical Data
-
基因名
PROS1
- Application
-
别名
Preproprotein S; Propiece of latent protein S; PROS 1; PROS; PROS_HUMAN; proS1; Protein S alpha; Protein Sa; PS 21; PS 22; PS 23; PS 24; PS 25; PS 26; PS21; PS22; PS23; PS24; PS25; PS26; PSA; THPH5; THPH6; Vitamin K dependent protein S; Vitamin K-dependent plasma protein S; Vitamin K-dependent protein S
-
种属
Human
-
表达系统
E. coli
-
标签
N- His-SUMO
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P07225
-
表达区间
42-676aa
-
分子量
86.6 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
PROS1, or Protein S, is a vitamin K-dependent plasma glycoprotein that plays a crucial role in the regulation of coagulation and anticoagulation processes. It is primarily synthesized in the liver and is essential for the proper functioning of the protein C pathway, which is vital for maintaining hemostatic balance. The study of PROS1 has garnered significant attention due to its involvement in various thrombotic disorders and its potential implications in other pathological conditions, including cancer and inflammatory diseases. Mutations in the PROS1 gene can lead to Protein S deficiency, resulting in an increased risk of thrombosis. Research on recombinant PROS1 (rPROS1) has advanced to explore its therapeutic potential, particularly in treating patients with Protein S deficiency. Advances in recombinant DNA technology have enabled the production of rPROS1, allowing for large-scale production and characterization of the protein. Studies have focused on optimizing its expression systems, enhancing stability, and assessing its functional activity in comparison to native Protein S. The development of rPROS1 could provide new avenues for the treatment of clotting disorders, contributing to the management of conditions associated with impaired anticoagulant pathways. As the understanding of PROS1's role in hemostasis deepens and the methodologies for producing recombinant proteins improve, the ongoing research aims to clarify the therapeutic applications of rPROS1 in clinical settings.
